The effect of resveratrol supplementation on biomarkers of liver health: A systematic review and meta‐analysis of randomized controlled trials

Abstract

AbstractThis study aimed to evaluate the effect of resveratrol on liver biomarkers in adult participants, using systematic review and meta‐analysis of randomized controlled trials. PubMed, Scopus, Web of Science and Cochran Library was searched, up to October 2021. The pooled effects were calculated using a random‐effects model and expressed as weighted mean difference and 95% confidence interval. The methodological quality of studies as well as certainty of evidence were assessed by standard tools. Thirty‐seven relevant trials were found. Although overall analysis found no significant change, subgroup analysis showed a significant improvement in alanine aminotransferase (ALT; −7.79 U/L) and glutamyl transferase (−6.0 U/L) in patients with liver disorders, and ALT (−2.22 U/L) in younger adults; however, high‐dose supplementation (>1,000 mg/day) appeared to increase alkaline phosphatase concentration (+5.07 U/L). ALT also increased in older adults (+2.33 U/L) following resveratrol supplementation. We found resveratrol did not have a significant effect on liver health in the general population. However, resveratrol could be effective in patients with liver disorders. Our findings also suggest that high‐dose resveratrol administration and supplementation in older adults should be performed with caution. Further high‐quality clinical trials are also needed to firmly establish the clinical efficacy of resveratrol.